The specialty chemicals sector has been a battlefield over the last year, and this phosgene-based heavyweight is no exception. While most players are struggling to keep their heads above water, this Gujarat-based entity is doubling down on infrastructure. However, the latest financial audit reveals a tightening grip on margins and a significant dent in annual profitability that should make every investor pause and look closer at the numbers.
1. At a Glance
The numbers coming out of the latest annual audit are a mix of aggressive expansion and operational pain. We are looking at a company that is the largest phosgene-based specialty chemical manufacturer in India, part of the century-old Alembic Group. But longevity doesn’t guarantee immunity from market cycles.
The Red Flags are waving in plain sight:
- Profit Erosion: Net Profit for the full year FY26 plummeted to ₹39.33 crore, down from ₹53.88 crore in the previous year. That is a massive 27% hit to the bottom line.
- The Debt Monster Awakens: After years of being virtually debt-free, the company has suddenly spiked its borrowings. Total borrowings now stand at ₹76.94 crore, compared to a negligible ₹2.50 crore just a year ago.
- Margin Compression: Operating Profit Margins (OPM) have shrunk from 31% to 28% annually, with quarterly volatility hitting as low as 23% in some periods.
- Working Capital Strain: Inventory days have exploded from 179 days to 292 days. The money is literally sitting in the warehouse, rotting away the return ratios.
The company is in the middle of a massive ₹250 crore capex cycle. While they have commissioned a new multipurpose plant in January 2026, the transition from a “capacity builder” to a “profit generator” is proving to be a slow and expensive climb. Investors are currently paying for the hope of future utilization while the current ROCE has tanked to 9.73%.
Is this a strategic masterstroke or a classic case of over-leveraging at the wrong time in the cycle?
2. Introduction
Paushak Ltd is not your average chemical company. It operates in the high-entry-barrier world of Phosgene chemistry. For the uninitiated, Phosgene is a highly toxic gas, and getting a license to manufacture it is harder than getting a front-row seat at a sold-out stadium.
Being part of the Alembic Group, the company carries a legacy that dates back to 1907. This pedigree provides it with a level of corporate governance and market access that many small-cap peers crave. However, the stock has been a laggard, delivering a -16% return over the last 3 years, clearly reflecting the market’s frustration with the delayed payoff from its massive capital expenditures.
The company recently underwent a structural change in its equity, completing a 3:1 bonus issue and a 1:2 stock split in late 2025 to improve liquidity. While these “shareholder-friendly” moves look good on paper, the underlying business is currently battling Chinese pricing pressure and a shift in its product mix that is testing its operational efficiency.
With the recent appointment of Mr. Jain Parkash as Whole-time Director, the management is signaling a shift toward more aggressive execution. But as we dive into the financials, the question remains: Can they fill the new 14,400 MT/year capacity fast enough to justify the debt?
3. Business Model – WTF Do They Even Do?
Think of Paushak as the “Scary Gas” specialist of the Indian chemical industry. They take Phosgene—a gas that requires extreme safety protocols—and turn it into high-value intermediates.
The Product Basket:
- Chloroformates & Isocyanates: These aren’t fancy coffee orders; they are essential building blocks for the pharmaceutical and agrochemical industries.
- Downstream Derivatives: The company is moving away from selling just the base gas to creating complex “multi-purpose” molecules.
The Catch: They are essentially a “toll manufacturer” for giant innovators. While they have a dominant market share in India, they are a small fish globally, with only 11% of
